Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Plus Therapeutics Inc PSTV

Healthcare Biotechnology
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma... see more

Recent & Breaking News (NDAQ:PSTV)

Plus Therapeutics Significantly Expands Investigational Oncology Drug Pipeline

GlobeNewswire January 6, 2022

Plus Therapeutics Announces Two Significant Milestones Toward cGMP Manufacture of its Lead Investigational Radiotherapeutic

GlobeNewswire January 4, 2022

Plus Therapeutics to Present at MedInvest Oncology Investor Conference

GlobeNewswire December 2, 2021

Plus Therapeutics Announces Positive Interim Data from ReSPECT(TM)-GBM Phase 1 Clinical Trial at the 2021 Society for Neuro-Oncology Annual Meeting

GlobeNewswire November 18, 2021

Plus Therapeutics Announces New Employment Inducement Grants

GlobeNewswire November 12, 2021

Plus Therapeutics Receives FDA Fast Track Designation for 186RNL Targeted Radiotherapeutic for Leptomeningeal Metastases

GlobeNewswire November 9, 2021

Plus Therapeutics to Host Key Opinion Leader Roundtable on ReSPECT(TM)-GBM Trial

GlobeNewswire November 3, 2021

Plus Therapeutics Announces Presentation of ReSPECT-GBM Trial Dosimetery Data at the American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting

GlobeNewswire October 27, 2021

Plus Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights

GlobeNewswire October 21, 2021

Plus Therapeutics Announces FDA Clearance of Investigational New Drug Application for 186RNL for the Treatment of Leptomeningeal Metastases

GlobeNewswire October 19, 2021

Plus Therapeutics to Announce Third Quarter 2021 Financial Results and Host Conference Call on October 21, 2021

GlobeNewswire October 14, 2021

Plus Therapeutics to Present ReSPECT(TM)-GBM Clinical Trial Data at the 2021 SNO Annual Meeting

GlobeNewswire September 30, 2021

Plus Therapeutics to Present at the Benzinga Healthcare Small Cap Conference

GlobeNewswire September 27, 2021

Plus Therapeutics to Present Rhenium-186 NanoLiposome Data at the American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting

GlobeNewswire September 23, 2021

Plus Therapeutics Announces the Appointment of Industry Veteran, Norman LaFrance, M.D., as the Company's Chief Medical Officer

GlobeNewswire September 13, 2021

Plus Therapeutics to Present at the H.C. Wainwright Global Investment Conference

GlobeNewswire September 8, 2021

Plus Therapeutics Announces Commercial Manufacturing Supply Agreement for Its Lead Investigational Drug

GlobeNewswire September 2, 2021

Plus Therapeutics Announces Presentation of Data from the ReSPECT(TM)-GBM Trial and Plans for Treating Pediatric Brain Cancer

GlobeNewswire August 21, 2021

Plus Therapeutics Presents Data from Preclinical Study of Rhenium-186 Nanoliposome in Leptomeningeal Metastases and Plans for Further Evaluation with Upcoming Phase 1 Clinical Trial

GlobeNewswire August 19, 2021

Plus Therapeutics to Present Data from ReSPECT(TM)-GBM Trial at the American Association of Neurological Surgeons 2021 Annual Scientific Meeting

GlobeNewswire August 13, 2021